SRS9

SRS9 is a developmentally regulated, bradyzoite-specific member of the SAG1-related sequence (SRS) family of putative surface proteins in Toxoplasma gondii, upregulated during the tachyzoite-to-bradyzoite differentiation that underlies chronic infection (PMID:12455982). It is the dominant surface antigen recognized by the bradyzoite-specific P36 monoclonal antibody (PMID:17368655). Functionally, SRS9 contributes to the maintenance of parasite persistence in the brain and to the control of reactivation: deletion of SRS9 reduces brain cyst loads during chronic infection and accelerates intestinal reactivation in immunosuppressed hosts (PMID:17261600). Its strict stage restriction is functionally important as an immune-evasion mechanism—forced constitutive expression of SRS9 in tachyzoites elicits an SRS9-specific IFN-γ response that progressively eliminates persisting cysts (PMID:15944311). This tachyzoite-stage repression is enforced transcriptionally by the ApiAP2 factor AP2IV-4, whose deletion causes ectopic SRS9 expression in replicating tachyzoites (PMID:29718996), and the SRS9 promoter is itself a functional driver of bradyzoite-stage gene expression (PMID:31572690). Beyond these surface-antigen and stage-regulation roles, no biochemical activity or molecular interaction partner of the SRS9 protein has been characterized in the available corpus.

1. 2002 Medium

   Established that SRS9 exists as a stage-regulated gene, framing it as a candidate surface protein of the developmental switch rather than a constitutive antigen.

   Evidence Microarray expression profiling of ~4,400 Toxoplasma cDNAs identifying developmental upregulation during tachyzoite-to-bradyzoite differentiation

   PMID:12455982

   Open questions at the time

   • Transcript-level only; protein expression, localization, and surface topology not shown
   • No function assigned
   • Family membership inferred from sequence similarity, not biochemical characterization
2. 2005 High

   Answered why SRS9 expression is stage-restricted, showing that confining it to bradyzoites shields the parasite from an SRS9-specific immune response that otherwise clears persisting cysts.

   Evidence Transgenic parasites constitutively expressing SRS9 in tachyzoites, mouse infection, IFN-γ measurement and brain cyst quantification

   PMID:15944311

   Open questions at the time

   • Does not define the SRS9 protein's biochemical role on the surface
   • Immune effector cell types and epitopes driving the IFN-γ response not resolved
3. 2007 High

   Identified SRS9 as the molecular target of the bradyzoite-specific P36 monoclonal antibody, providing a defined reagent for detecting the protein.

   Evidence Stable transfection in BSR4-negative strains, Western blotting, and reciprocal immunoprecipitation with P36 mAb

   PMID:17368655

   Open questions at the time

   • Epitope and antibody effect on parasite function not characterized
   • Does not address native binding partners or ligands of SRS9
4. 2007 High

   Demonstrated a genetic requirement for SRS9 in chronic persistence and reactivation control, moving it from marker to functional contributor.

   Evidence ΔSRS9 knockout in a bioluminescent strain, oral and intraperitoneal mouse infection, bioluminescence imaging, brain cyst counts, and dexamethasone-induced reactivation

   PMID:17261600

   Open questions at the time

   • Molecular mechanism by which SRS9 promotes persistence or restrains reactivation unknown
   • No host receptor or interaction partner identified
5. 2018 High

   Identified the upstream transcriptional switch enforcing SRS9 stage-specificity, explaining how tachyzoite-stage repression is achieved.

   Evidence Genetic deletion of the AP2IV-4 locus with protein detection of ectopic SRS9 (and other bradyzoite proteins) in tachyzoites plus mouse infection

   PMID:29718996

   Open questions at the time

   • Whether AP2IV-4 binds the SRS9 promoter directly or acts indirectly not established
   • cis-regulatory elements of SRS9 not mapped
6. 2019 Medium

   Confirmed the SRS9 promoter as a bona fide bradyzoite-stage-specific expression driver, providing a tool leveraging its stage restriction.

   Evidence GRA17 complementation under the SRS9 promoter with bradyzoite viability assays and mouse infection in ME49

   PMID:31572690

   Open questions at the time

   • Functional readout attributed to GRA17, not SRS9 protein; SRS9's own role not tested here
   • Promoter architecture and regulatory element boundaries not defined

• The biochemical function of the SRS9 protein on the bradyzoite surface—its ligand, host receptor, or adhesion/immune-modulatory activity—remains unresolved.
• No structural model of SRS9
• No identified host or parasite interaction partner
• Mechanism linking surface expression to persistence and reactivation control unknown